Chromocell Therapeutics Corp
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
PTHS$9.37+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| September 30, 2024 (Unaudited) | December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash | $1,254,903 | $96,391 |
| Prepaid expenses | 94,585 | — |
| Due from Chromocell Corporation | 40,400 | — |
| Deferred offering costs | 750,000 | — |
| TOTAL CURRENT ASSETS | 2,139,888 | 96,391 |
| TOTAL ASSETS | $2,139,888 | $96,391 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued expenses | $1,279,487 | $4,620,925 |
| Accrued compensation | 308 | 645,947 |
| Bridge loan, net of debt discount | — | 316,324 |
| Loan payable, net of debt discount | 2,155,719 | 202,279 |
| Loan payable - related party, net of debt discount | 131,868 | 750,082 |
| Due to Chromocell Corporation | — | 5,386 |
| TOTAL CURRENT LIABILITIES | 3,567,382 | 6,540,943 |
| TOTAL LIABILITIES | 3,567,382 | 6,540,943 |
| COMMITMENTS AND CONTINGENCIES | ||
| STOCKHOLDERS’ DEFICIT | ||
| Preferred stock Series A, $0.0001 par value, 700,000 shares authorized, 0 and 600,000 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | — | 60 |
| Preferred stock Series C, $0.0001 par value, 5,000 shares authorized, 2,600 and 0 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | — | — |
| Common stock, $0.0001 par value, 200,000,000 shares authorized, 5,818,111 and 3,906,300 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 583 | 391 |
| Additional paid in capital | 18,120,176 | 7,074,646 |
| Accumulated deficit | (19,548,253) | (13,519,649) |
| TOTAL STOCKHOLDERS’ DEFICIT | (1,427,494) | (6,444,552) |
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | $2,139,888 | $96,391 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.